Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr2.80 SEK
Change Today +0.01 / 0.36%
Volume 210.8K
BINV On Other Exchanges
As of 11:29 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

bioinvent international ab (BINV) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/16/14 - kr3.03
52 Week Low
03/23/15 - kr1.72
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

bioinvent international ab (BINV) Related Businessweek News

No Related Businessweek News Found

bioinvent international ab (BINV) Details

BioInvent International AB (publ), a research-based pharmaceutical company, focuses on the discovery and development of antibody-based drugs against cancer. The company’s products under development include BI-505, a human antibody that is in Phase II clinical trial for the treatment of multiple myeloma; BI-1206, an antagonistic antibody aimed at the immunosuppressive target protein Fc gamma receptor IIB, CD32b, which is overexpressed on tumour cells in patients with lymphoma; and TB-403, an antibody, which is in Phase I clinical trial for the treatment of medulloblastoma. It has research collaborations with external partners, such as Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Servier, Xoma, and the University of Southampton. The Company was founded in 1997 and is based in Lund, Sweden.

39 Employees
Last Reported Date: 07/22/15
Founded in 1997

bioinvent international ab (BINV) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr2.0M
Compensation as of Fiscal Year 2014.

bioinvent international ab (BINV) Key Developments

BioInvent International AB Reports Earnings Results for the Six Months Ended June 30, 2015

BioInvent International AB reported earnings results for the six months ended June 30, 2015. Loss for the six months ended June 30, 2015 was SEK 46.97 million, or SEK 0.39 loss per share, compared to a loss of SEK 15.22 million, or SEK 0.17 loss per share, for the same period ended June 30, 2014. Net sales for the six months ended June 30, 2015 were SEK 4.27 million, compared to SEK 34.21 million for the same period ended June 30, 2014.

BioInvent International AB Reports Earnings Results for the Second Quarter Ended June 2015

BioInvent International AB reported that it recorded a loss after tax of SEK 25 million, or SEK 0.19 per diluted share, for the second quarter of 2015, from April 2015 to June 2015. This was a decline over profit after tax of SEK 3.7 million, or SEK 0.04 per diluted share, in the second quarter of 2014. Net sales for the quarter were SEK 3.7 million, as compared with SEK 32 million in the second quarter of 2014.

BioInvent International Progresses Collaboration with US Biotechnology Company

BioInvent International announced that its partnership with U.S. biotechnology company advances to next phase. The collaboration aims to discover novel therapeutic antibodies to be incorporated into the U.S. company's CAR-T programs. The unnamed biotech company signed earlier this year a license to get access to BioInvent's unique ability to discover antibodies with the antibody library n-CoDeR. The first of up to three targets covered by the agreement has now been identified and the work to develop appropriate antibodies can thus be initiated. Under the license agreement BioInvent may receive revenue in the form of potential clinical milestone payments and royalties on future sales of any product developed as a result of the collaboration. In addition, BioInvent is in the early phase of the collaboration entitled to limited compensation for the work to identify antibodies against the first target.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BINV:SS kr2.80 SEK +0.01

BINV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €12.52 EUR -0.07
arGEN-X BV €10.13 EUR 0.00
Genmab A/S kr591.50 DKK -18.50
ImmunoGen Inc $14.28 USD 0.00
XOMA Corp $0.86 USD +0.0388
View Industry Companies

Industry Analysis


Industry Average

Valuation BINV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.4x
Price/Book 6.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOINVENT INTERNATIONAL AB, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at